Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check6 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.4.2; the prior government-funding lapse notice and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check41 days agoChange DetectedNotice: Added a government funding lapse banner and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a 'Show glossary' option and updated footer labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with the site revision updated to v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check62 days agoChange DetectedThe page metadata was updated: 'Type 2 diabetes' added with related topic 'MedlinePlus Genetics', and the page revision updated from v3.3.3 to v3.3.4.SummaryDifference0.2%

- Check76 days agoChange DetectedType 2 diabetes and the related topics MedlinePlus Genetics were removed from the page's topics/MeSH section.SummaryDifference0.2%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.